NBTK.DE vs. XBI
Compare and contrast key facts about Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and SPDR S&P Biotech ETF (XBI).
NBTK.DE and XBI are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. NBTK.DE is a passively managed fund by Invesco that tracks the performance of the Nasdaq Biotechnology. It was launched on Nov 6, 2014. XBI is a passively managed fund by State Street that tracks the performance of the S&P Biotechnology Select Industry Index. It was launched on Feb 6, 2006. Both NBTK.DE and XBI are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: NBTK.DE or XBI.
Correlation
The correlation between NBTK.DE and XBI is 0.58, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Performance
NBTK.DE vs. XBI - Performance Comparison
Key characteristics
NBTK.DE:
0.32
XBI:
-0.09
NBTK.DE:
0.55
XBI:
0.04
NBTK.DE:
1.07
XBI:
1.00
NBTK.DE:
0.32
XBI:
-0.04
NBTK.DE:
1.10
XBI:
-0.25
NBTK.DE:
5.11%
XBI:
9.29%
NBTK.DE:
17.67%
XBI:
24.62%
NBTK.DE:
-30.99%
XBI:
-63.89%
NBTK.DE:
-7.93%
XBI:
-47.73%
Returns By Period
In the year-to-date period, NBTK.DE achieves a 2.58% return, which is significantly higher than XBI's 0.79% return.
NBTK.DE
2.58%
2.08%
-1.40%
5.68%
4.03%
N/A
XBI
0.79%
4.74%
-7.09%
-0.26%
-1.26%
3.14%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
NBTK.DE vs. XBI - Expense Ratio Comparison
NBTK.DE has a 0.40% expense ratio, which is higher than XBI's 0.35% expense ratio.
Risk-Adjusted Performance
NBTK.DE vs. XBI — Risk-Adjusted Performance Rank
NBTK.DE
XBI
NBTK.DE vs. XBI - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) and SPDR S&P Biotech ETF (XBI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
NBTK.DE vs. XBI - Dividend Comparison
NBTK.DE has not paid dividends to shareholders, while XBI's dividend yield for the trailing twelve months is around 0.15%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NBTK.DE Invesco Nasdaq Biotech UCITS ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XBI SPDR S&P Biotech ETF | 0.15% | 0.15% | 0.02% | 0.00% | 0.04% | 0.20% | 0.00% | 0.28% | 0.24% | 0.26% | 0.61% | 1.07% |
Drawdowns
NBTK.DE vs. XBI - Drawdown Comparison
The maximum NBTK.DE drawdown since its inception was -30.99%, smaller than the maximum XBI drawdown of -63.89%. Use the drawdown chart below to compare losses from any high point for NBTK.DE and XBI. For additional features, visit the drawdowns tool.
Volatility
NBTK.DE vs. XBI - Volatility Comparison
The current volatility for Invesco Nasdaq Biotech UCITS ETF (NBTK.DE) is 5.65%, while SPDR S&P Biotech ETF (XBI) has a volatility of 6.19%. This indicates that NBTK.DE experiences smaller price fluctuations and is considered to be less risky than XBI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.